Patent echoes for Viralytics

By Kate McDonald
Monday, 30 March, 2009

Sydney company Viralytics has received a patent in the US for its range of echoviruses, which aim to bind to and infect cancer cells.

The echovirus type 1 (EV1) binds to cells expressing integrin alpha2 beta 2, a receptor on the cell surface receptor highly expressed in some cancers, particularly prostate, ovarian and gastric tumours.

Viralytics has a proprietary formulation of EV1 called Evatak, as well as a formulation for a subset of coxsackie A viruses called Cavatak. Cavatak binds to the receptors intercellular adhesion molecule-1 and decay accelerating factor.

The company is running Phase I trials of Cavatak in melanoma, prostate, breast and head and neck cancers.

Related News

Less penicillin needed to treat Strep A infection than we thought

It's never been known exactly how much penicillin prevents sore throats — the most...

Stress disrupts emotion control in mental illness

Acute stress may impair key brain functions involved in managing emotions — particularly in...

Organoid platform enables closer study of bat-borne viruses

Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd